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INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
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INTRODUCTION 
The incidence of status epilepticus ranges from 10.3 to 
61.0 per 100 000 people, with the highest incidence 
reported in populations with low socioeconomic 
standards of living and quality of health care. The 
incidence of status epilepticus is high in the young and 
the old. 1, 2 There are an estimated 3 million cases of 
status epilepticus worldwide each year; of which 70% 
are generalized convulsive status epilepticus (GCSE) 
and about 75% of these cases are overt GCSE. 2, 3 The 
other main category is that of non-convulsive status 
epilepticus (NCSE). GCSE is associated with substantial 
mortality and morbidity. 2, 3 Electrolyte disturbances in the 
ICU are most common. Low magnesium, phosphate, and 
both very low and very high calcium values can cause 
seizures. Critical care physicians must be vigilant to 
suspect and identify electrolyte disturbances in their 
patients, because they are potentially a cause, of poor 
prognosis. 4 The main causes of status epilepticus include 
low blood concentrations of antiepileptic drugs in patients 
with chronic epilepsy, cerebrovascular accidents, anoxia or 
hypoxia, metabolic causes, alcohol or illicit drug 
withdrawal and miscellaneous causes. 5, 6 Despite recent 
improvements in its diagnosis and treatment, status 
epilepticus is still associated with significant mortality. 
Patients presenting with seizures show that main 
laboratory abnormalities present are leukocytosis, 
metabolic acidosis, anemia and hypomagnesaemia. 5 It 
is now common practice to obtain a complete blood 
count and chemistry profiles routinely in patients 
presenting with status epilepticus as electrolytes (e.g. 
sodium, calcium) abnormalities or basic metabolic 
disorders (glucose). 5, 6 The correct diagnosis of seizures 
secondary to these electrolyte abnormalities warrants 
sharp thinking and meticulous search as seizures may 
be the sole presenting symptom of electrolyte 
imbalance. Identification and correction of electrolyte 
imbalances is a potentially manageable ailment that 
can effectively reduce the proportion of morbidity and 
mortality associated with hypocalcemic and hypomagne- 
semic seizures. There is insufficient local data on 
evaluation of electrolyte imbalances in epilepsy in 
Pakistan and therefore, health care takers at primary and 
secondary care levels are unable to acknowledge a 
potentially treatable cause of epilepsy without long term 
use of antiepileptics. The objective of this article is to 
delineate the percentage of people with status 
epilepticus having calcium and magnesium deficiencies 
at admission in order to highlight the importance of early 
recognition and therefore prompt targeted treatment of 
electrolyte related seizures. 
MATERIALS AND METHODS
The study was carried out on inpatient of department of 
Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad from April 2013 to October 2013. 
Seventy patients diagnosed with status epilepticus 
aged more than 12 years were included. The study was 
approved by hospital ethical committee and carried out 
according to international ethical standards of the 
responsible committee on human experimentation and 
with the latest version of Helsinki Declaration of 1975. 
Patients fulfilling the inclusion criteria were enrolled 
after taking informed written consent from the patients 
or relatives. Following information was collected: 
demographic data (age, gender), history of pre-existing 
epilepsy and use of antiepileptic drugs (AED), drug 
withdrawal, noncompliance to medication, clinical 
presentation (to ascertain/ define status epilepticus), 
routine laboratory tests, toxicology screen and brain 
imaging to ascertain the likely cause of status 
epilepticus. Routine laboratory investigations done in all 
patients at admission included complete blood counts, 
ESR, liver function tests, renal function tests, blood 
sugar random, serum electrolytes (sodium, potassium, 
calcium, phosphate and magnesium), urine routine 
examination, urine culture, blood cultures, arterial 
blood gases, serum albumin and AED drug levels. 
Corrected calcium was calculated for those with 
hypoalbuminemia. EEG was done in all patients within 
24 to 48 hours of admission to monitor progress of 
management, to diagnose non-convulsive status 
epilepticus and to rule out other related abnormalities 
(e.g., encephalitis). Lumbar puncture (for CSF routine 
examination) and brain imaging (CT scan or MRI brain) 
was done in selected patients as per indications. All 
patients were managed according to the standard 
protocol for status epilepticus, along with full supportive 
care and cause specific treatment. Causes of status 
epilepticus were identified on the basis of history, 
physical examination, laboratory investigations, and/or 
neuroimaging studies. Factors precipitating status 
epilepticus were classified as: non compliance to 
antiepileptic drug, AED discontinuation within 48 hours 
(drug withdrawal), CNS infection, cerebrovascular 
disease, CNS structural lesions, systemic infections, 
metabolic/ electrolyte disturbances, illicit drugs/alcohol 
abuse, poisoning or idiopathic. The diagnosis of 
idiopathic status epilepticus was made if no apparent 
etiology was identified. The data was analyzed using 
SPSS version 16.0 (USA Inc.). Mean, Median, Mode, 
range and standard deviation were calculated for 
numerical variables i.e. age, serum calcium and 
magnesium. Frequency and percentages were 
presented for categorical variables i.e. gender, serum 
calcium and magnesium (normal, low, high), known 
epileptics, epileptics on AEDs and drug withdrawal.
RESULTS
Mean age was 32.8 ± 5.4 years, median was 27.5 
years and mode was 22 years; with an age range of 77 
(13-90) years. Among the 70 patients, 46 (46 out of 
70; 65.7%) were females and 24 (24 out of 70; 
34.3%) were males (Figure 1). 21 (21 out of 70; 30%) 
were known epileptics out of which 16 (16 out of 21; 
76.1%) were on regular antiepileptic treatment. In 
those patients who were on antiepileptic drugs, there 
was history of antiepileptic drug withdrawal in 8 (8 out 
of 16; 50%) patients when they presented in status. 
Calcium level was low in 29 (29 out of 70; 41.4%) 
patients while it was normal in 41 (41 out of 70; 
58.6%) patients. Range of calcium values was 
1.24-2.50 mmol/ l with mean of 2.13 ± 0.24 mmol/l. 
Previously undiagnosed epileptics had low calcium in 
19 (19 out of 49; 38.7%) patients. Previously 
diagnosed epileptics had low calcium in 10 (10 out of 
21; 47.6%) patients. Those who were on antiepileptic 
drugs, 8 (8 out of 16; 50%) had low calcium levels. 
Overall, 9 (9 out of 24; 37.5%) male patients and 20 
(20 out of 46; 43.4%) females had low calcium values. 
Magnesium level was low only in 7 (7 out of 70; 10%) 
patients and it was normal in 63 (63 out of 70; 90%) 
patients. Range of Magnesium values was 0.25-1.00 
mmol/l with mean value of 0.81 ± 0.15 mmol/l. 
Previously undiagnosed epileptics had low magnesium 
in 4 (4 out of 49; 8.1%) patients. Previously diagnosed 
epileptics had low magnesium in 3 (3 out of 21; 
14.2%) patients. Those who were on antiepileptic 
drugs, 6 (6 out of 16; 37.5%) had low magnesium 
levels. Overall, 2 (2 out of 24; 8.3%) male patients and 
5 (5 out of 46; 10.8%) females had low magnesium 
values. Both calcium & magnesium levels were low in 7 
(7 out of 70; 10%) patients (Figure 1). Comparison of 
gender showed that proportion of status was almost 
double in females (female:male 1.9:1). All those with 
hypomagnesaemia invariably had hypocalcaemia. 
DISCUSSION
Electrolyte abnormalities affect many organs and 
tissues, including the brain. Most of the clinical 
manifestations of electrolyte abnormalities are 
predominantly neurologic and parallel the severity of 
neuronal damage.7, 8 Acute and severe electrolyte 
abnormalities may appear with seizures, or with rapidly 
progressive neurologic symptoms and signs, which 
needs emergency treatment. Seizures are especially 
common in patients with hypocalcemia and 
hypomagnesemia. Seizures occur in 20–25% of 
patients with acute hypocalcemia as a medical 
emergency, and in 30–70% of patients with 
symptomatic hypoparathyroidism. 9, 10 Successful 
management of seizures starts with the establishment 
of an accurate diagnosis of the underlying electrolyte 
abnormalities, because rapid identification and 
correction of the disturbance is important to control 
seizures and prevent permanent brain damage. 11, 12 
Electrolyte (e.g., sodium, calcium) abnormalities or 
basic metabolic disorders (glucose) are reported in 
some patients with status. 13, 14 Generalized tonic- 
clonic, focal motor, and (less frequently) atypical 
absence or akinetic seizures may be the sole presenting 
symptom in hypocalcemia. 10 Generalized tonic–clonic 
seizures can occur in neonates and adults in 
association with severe hypomagnesemia as well. 15, 16 
According to one study, 10% of patients had a 
metabolic disorder as the primary underlying etiology of 
status epilepticus. 13 According to our study, 41.4% of 
patients presenting as status had low calcium level 
which is higher percentage than the percentage 
reported in previous studies. 13 According to our study, 
magnesium level was low in 10% patients who 
presented in status epilepticus. Our results are 
comparable to that of Aguset al. who showed that 
hypomagnesemia occurs in nearly 12 % of hospitalized 
patients. 14 According to Singhiet al., magnesium 
disturbances in critically ill children admitted to 
pediatric intensive care unit show that hypocalcemia 
and hypermagnesaemia occurs in 60% and 4% of 
patients, respectively. The incidence of low RBC-Mg 
(magnesium) in their study was 17.3 episodes per 100 
patient days. Mortality was nine-fold higher in 
hypomagnesemic (30%) compared with normomagna- 
esemic (3.3%) patients. If magnesium and calcium 
both were low, the mortality rate was 33% in contrast to 
nil if both were normal. 17 According to our study, both 
calcium & magnesium levels were low in 10% of 
patients who presented in status. Reportedly, most 
patients with acute symptomatic convulsive status 
epilepticus have either acute metabolic derangement 
(electrolyte imbalance, hypoglycemia, hypocalcemia, or 
hypomagnesemia) or an acute CNS infection. 17, 18 A 
study from Pakistan by Khalid et al.  showed high male 
to female ratio i-e-, 2.4 to 3:1 for these electrolyte 
abnormalities while our study showed that 65.7% were 
females and 34.3% were males (1.9:1) i-e-, high 
female to male ratio (Figure 1). 5
Figure 1: Frequency of normal and abnormal calcium 
and magnesium levels among males & females. 
According to our study, 30% were known epileptics out 
of which 76% were on antiepileptic treatment. Among 
these, there was history of antiepileptic drug withdrawal 
in 50% when they presented in status. In a study by 
Aminoffet al., the etiology, clinical features and 
outcome of status epilepticus in 98 patients over the 
age of 14 years have been reviewed. The most common 
single cause of the status was noncompliance with 
anticonvulsants and this accounted for status in 53% of 
patients which is almost similar to our findings. 19 Non- 
convulsive status epilepticus secondary to hypocalcemia 
has also been reported. Seizures can occur without 
muscular tetany in patients with hypocalcemia. EEG 
changes associated with hypocalcemia include 
evolution from alpha through theta and delta 
dominance. Other EEG findings are generalized spikes, 
sharp-waves burst of delta activity with sharp 
components. 2,20 Because neurologic symptoms of 
electrolyte disorders are functional rather than 
structural, the neurologic manifestations of electrolyte 
disturbances are typically reversible. 11, 12 Electrolyte 
homeostasis in the central nervous system is very 
essential for brain function. 13, 18 Regulation of ionic 
balance is an essential process involving a complex 
array of molecules for moving ions into and out of the 
brain and involving blood–brain barrier function as well 
as mechanisms in the membranes of both neurons and 
glia. Alterations in ion gradients across cellular 
membranes have direct and indirect effects on 
neuronal discharge and may facilitate epileptiform 
activities. 21, 22 Hypocalcemia and hypomagnesemia 
cause mainly CNS neuronal irritability with seizures. 
When the extracellular concentration of calcium ions 
falls below normal, the nervous system becomes 
progressively more excitable, because this causes 
neuronal membrane permeability to sodium ions, 
allowing easy initiation of action potentials. At plasma 
calcium ion concentrations about 50 percent below 
normal, the peripheral nerve fibers become so excitable 
that they begin to discharge spontaneously, initiating 
trains of nerve impulses that passes to the peripheral 
skeletal muscles to elicit tetanic muscle contraction. 
Consequently, hypocalcemia causes tetany and seizures 
because of its action of increasing excitability in the 
brain. As mechanics of calcium at cellular level are 
dependent on serum magnesium levels, hypomagnesemia 
via causing hypocalcemia causes the same (Figure 2). 18, 22
Figure 2: Molecular mechanisms behind seizures 
secondary to hypocalcaemia: Hypocalcaemia facilitates 
movement of sodium ions into the nerve, thus causing 
spontaneous discharge of electrical activity.
Main treatment for hypocalcemic seizures is calcium 
replacement; AEDs are typically not needed. AEDs may 
abolish both overt and latent tetany, whereas hypocalcemic 
seizures remain refractory. However, those in status may 
benefit from AEDs. The inhibition of N-methyl-d-aspartate 
(NMDA) glutamate receptors and the increased production 
of vasodilator prostaglandins in the brain is the 
anticonvulsant action of magnesium. Magnesium serves to 
stabilize neuronal membranes and the lack of it explains 
the tendency to have seizures in the first place. 23, 24 Also, 
mechanism of calcium regulation on neurons is coherent 
with magnesium levels and hypomagnesaemia in itself 
interferes with the action of calcium at cellular level. 12, 16 In 
the setting of seizures or symptomatic or severe (<1.2 
mg/dl, <1 mEq/L) hypomagnesemia, it is advisable to 
inject 1-2 g of MgSO4 (magnesium sulfate) over a 5-min 
period, to be followed by an infusion of 1-2 g of MgSO4 per 
hour for the next few hours. If seizures persist, the bolus 
may be repeated. 17, 24 Serum calcium level is tightly 
regulated by parathyroid hormone (PTH) and 1, 25-dihydox 
-yvitamin D in humans. It is important that one should take 
a look at background factors that have significant effects 
on calcium and its’ regulating hormones. Among these, 
vitamin D insufficiency, magnesium depletion and 
treatment with bisphosphonates, glucocorticoids and 
anticonvulsants are most important. A complete workup of 
epilepsy, therefore, should include workup for calcium, 
magnesium, phosphorus, albumin, vitamin D and PTH 
levels at least in addition to brain imaging and EEG (electro 
encephalogram). 11, 15 Status epilepticus is an under 
diagnosed entity in Pakistan. It is a potentially reversible 
condition but has a high mortality if not recognized and 
managed on time. 25 According to our study, among those 
on antiepileptic drugs, 50% had low calcium levels while 
37.5% had low magnesium levels. Keeping the above 
statistics in mind, it is suggested that patients on long term 
AEDs should at least be worked up once in detail for 
electrolyte abnormalities as timely identification and 
correction can help reduce the morbidity and mortality 
associated with future status epilpeticus. As such, in the 
long run, being a potentially treatable cause, epilepsy 
secondary to electrolyte imbalances can be effectively 
treated without long term unnecessary use of antiepileptics 
and can help reduce both the burden of follow-up epilepsy 
in neurology clinics as well burden of cost on both the 
patients and the health care system.
CONCLUSION
Calcium level was abnormal in 41.4% of patients while 
magnesium was low in 10% of patients. Serum calcium 
level was lower in nearly half while magnesium in nearly 
2/5th of the previously diagnosed epileptics who presented 
in status. Among those on antiepileptic drugs, 50% had low 
calcium levels while 37.5% had low magnesium levels. It is 
suggested that all epileptic patients, especially those on 
long term AEDs, should at least be worked up once in detail 
for electrolyte abnormalities as timely identification and 
correction can help reduce the morbidity and mortality 
associated with future status epilepticus.
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
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observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
INTRODUCTION 
The incidence of status epilepticus ranges from 10.3 to 
61.0 per 100 000 people, with the highest incidence 
reported in populations with low socioeconomic 
standards of living and quality of health care. The 
incidence of status epilepticus is high in the young and 
the old. 1, 2 There are an estimated 3 million cases of 
status epilepticus worldwide each year; of which 70% 
are generalized convulsive status epilepticus (GCSE) 
and about 75% of these cases are overt GCSE. 2, 3 The 
other main category is that of non-convulsive status 
epilepticus (NCSE). GCSE is associated with substantial 
mortality and morbidity. 2, 3 Electrolyte disturbances in the 
ICU are most common. Low magnesium, phosphate, and 
both very low and very high calcium values can cause 
seizures. Critical care physicians must be vigilant to 
suspect and identify electrolyte disturbances in their 
patients, because they are potentially a cause, of poor 
prognosis. 4 The main causes of status epilepticus include 
low blood concentrations of antiepileptic drugs in patients 
with chronic epilepsy, cerebrovascular accidents, anoxia or 
hypoxia, metabolic causes, alcohol or illicit drug 
withdrawal and miscellaneous causes. 5, 6 Despite recent 
improvements in its diagnosis and treatment, status 
epilepticus is still associated with significant mortality. 
Patients presenting with seizures show that main 
laboratory abnormalities present are leukocytosis, 
metabolic acidosis, anemia and hypomagnesaemia. 5 It 
is now common practice to obtain a complete blood 
count and chemistry profiles routinely in patients 
presenting with status epilepticus as electrolytes (e.g. 
sodium, calcium) abnormalities or basic metabolic 
disorders (glucose). 5, 6 The correct diagnosis of seizures 
secondary to these electrolyte abnormalities warrants 
sharp thinking and meticulous search as seizures may 
be the sole presenting symptom of electrolyte 
imbalance. Identification and correction of electrolyte 
imbalances is a potentially manageable ailment that 
can effectively reduce the proportion of morbidity and 
mortality associated with hypocalcemic and hypomagne- 
semic seizures. There is insufficient local data on 
evaluation of electrolyte imbalances in epilepsy in 
Pakistan and therefore, health care takers at primary and 
secondary care levels are unable to acknowledge a 
potentially treatable cause of epilepsy without long term 
use of antiepileptics. The objective of this article is to 
delineate the percentage of people with status 
epilepticus having calcium and magnesium deficiencies 
at admission in order to highlight the importance of early 
recognition and therefore prompt targeted treatment of 
electrolyte related seizures. 
MATERIALS AND METHODS
The study was carried out on inpatient of department of 
Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad from April 2013 to October 2013. 
Seventy patients diagnosed with status epilepticus 
aged more than 12 years were included. The study was 
approved by hospital ethical committee and carried out 
according to international ethical standards of the 
responsible committee on human experimentation and 
with the latest version of Helsinki Declaration of 1975. 
Patients fulfilling the inclusion criteria were enrolled 
after taking informed written consent from the patients 
or relatives. Following information was collected: 
demographic data (age, gender), history of pre-existing 
epilepsy and use of antiepileptic drugs (AED), drug 
withdrawal, noncompliance to medication, clinical 
presentation (to ascertain/ define status epilepticus), 
routine laboratory tests, toxicology screen and brain 
imaging to ascertain the likely cause of status 
epilepticus. Routine laboratory investigations done in all 
patients at admission included complete blood counts, 
ESR, liver function tests, renal function tests, blood 
sugar random, serum electrolytes (sodium, potassium, 
calcium, phosphate and magnesium), urine routine 
examination, urine culture, blood cultures, arterial 
blood gases, serum albumin and AED drug levels. 
Corrected calcium was calculated for those with 
hypoalbuminemia. EEG was done in all patients within 
24 to 48 hours of admission to monitor progress of 
management, to diagnose non-convulsive status 
epilepticus and to rule out other related abnormalities 
(e.g., encephalitis). Lumbar puncture (for CSF routine 
examination) and brain imaging (CT scan or MRI brain) 
was done in selected patients as per indications. All 
patients were managed according to the standard 
protocol for status epilepticus, along with full supportive 
care and cause specific treatment. Causes of status 
epilepticus were identified on the basis of history, 
physical examination, laboratory investigations, and/or 
neuroimaging studies. Factors precipitating status 
epilepticus were classified as: non compliance to 
antiepileptic drug, AED discontinuation within 48 hours 
(drug withdrawal), CNS infection, cerebrovascular 
disease, CNS structural lesions, systemic infections, 
metabolic/ electrolyte disturbances, illicit drugs/alcohol 
abuse, poisoning or idiopathic. The diagnosis of 
idiopathic status epilepticus was made if no apparent 
etiology was identified. The data was analyzed using 
SPSS version 16.0 (USA Inc.). Mean, Median, Mode, 
range and standard deviation were calculated for 
numerical variables i.e. age, serum calcium and 
magnesium. Frequency and percentages were 
presented for categorical variables i.e. gender, serum 
calcium and magnesium (normal, low, high), known 
epileptics, epileptics on AEDs and drug withdrawal.
RESULTS
Mean age was 32.8 ± 5.4 years, median was 27.5 
years and mode was 22 years; with an age range of 77 
(13-90) years. Among the 70 patients, 46 (46 out of 
70; 65.7%) were females and 24 (24 out of 70; 
34.3%) were males (Figure 1). 21 (21 out of 70; 30%) 
were known epileptics out of which 16 (16 out of 21; 
76.1%) were on regular antiepileptic treatment. In 
those patients who were on antiepileptic drugs, there 
was history of antiepileptic drug withdrawal in 8 (8 out 
of 16; 50%) patients when they presented in status. 
Calcium level was low in 29 (29 out of 70; 41.4%) 
patients while it was normal in 41 (41 out of 70; 
58.6%) patients. Range of calcium values was 
1.24-2.50 mmol/ l with mean of 2.13 ± 0.24 mmol/l. 
Previously undiagnosed epileptics had low calcium in 
19 (19 out of 49; 38.7%) patients. Previously 
diagnosed epileptics had low calcium in 10 (10 out of 
21; 47.6%) patients. Those who were on antiepileptic 
drugs, 8 (8 out of 16; 50%) had low calcium levels. 
Overall, 9 (9 out of 24; 37.5%) male patients and 20 
(20 out of 46; 43.4%) females had low calcium values. 
Magnesium level was low only in 7 (7 out of 70; 10%) 
patients and it was normal in 63 (63 out of 70; 90%) 
patients. Range of Magnesium values was 0.25-1.00 
mmol/l with mean value of 0.81 ± 0.15 mmol/l. 
Previously undiagnosed epileptics had low magnesium 
in 4 (4 out of 49; 8.1%) patients. Previously diagnosed 
epileptics had low magnesium in 3 (3 out of 21; 
14.2%) patients. Those who were on antiepileptic 
drugs, 6 (6 out of 16; 37.5%) had low magnesium 
levels. Overall, 2 (2 out of 24; 8.3%) male patients and 
5 (5 out of 46; 10.8%) females had low magnesium 
values. Both calcium & magnesium levels were low in 7 
(7 out of 70; 10%) patients (Figure 1). Comparison of 
gender showed that proportion of status was almost 
double in females (female:male 1.9:1). All those with 
hypomagnesaemia invariably had hypocalcaemia. 
DISCUSSION
Electrolyte abnormalities affect many organs and 
tissues, including the brain. Most of the clinical 
manifestations of electrolyte abnormalities are 
predominantly neurologic and parallel the severity of 
neuronal damage.7, 8 Acute and severe electrolyte 
abnormalities may appear with seizures, or with rapidly 
progressive neurologic symptoms and signs, which 
needs emergency treatment. Seizures are especially 
common in patients with hypocalcemia and 
hypomagnesemia. Seizures occur in 20–25% of 
patients with acute hypocalcemia as a medical 
emergency, and in 30–70% of patients with 
symptomatic hypoparathyroidism. 9, 10 Successful 
management of seizures starts with the establishment 
of an accurate diagnosis of the underlying electrolyte 
abnormalities, because rapid identification and 
correction of the disturbance is important to control 
seizures and prevent permanent brain damage. 11, 12 
Electrolyte (e.g., sodium, calcium) abnormalities or 
basic metabolic disorders (glucose) are reported in 
some patients with status. 13, 14 Generalized tonic- 
clonic, focal motor, and (less frequently) atypical 
absence or akinetic seizures may be the sole presenting 
symptom in hypocalcemia. 10 Generalized tonic–clonic 
seizures can occur in neonates and adults in 
association with severe hypomagnesemia as well. 15, 16 
According to one study, 10% of patients had a 
metabolic disorder as the primary underlying etiology of 
status epilepticus. 13 According to our study, 41.4% of 
patients presenting as status had low calcium level 
which is higher percentage than the percentage 
reported in previous studies. 13 According to our study, 
magnesium level was low in 10% patients who 
presented in status epilepticus. Our results are 
comparable to that of Aguset al. who showed that 
hypomagnesemia occurs in nearly 12 % of hospitalized 
patients. 14 According to Singhiet al., magnesium 
disturbances in critically ill children admitted to 
pediatric intensive care unit show that hypocalcemia 
and hypermagnesaemia occurs in 60% and 4% of 
patients, respectively. The incidence of low RBC-Mg 
(magnesium) in their study was 17.3 episodes per 100 
patient days. Mortality was nine-fold higher in 
hypomagnesemic (30%) compared with normomagna- 
esemic (3.3%) patients. If magnesium and calcium 
both were low, the mortality rate was 33% in contrast to 
nil if both were normal. 17 According to our study, both 
calcium & magnesium levels were low in 10% of 
patients who presented in status. Reportedly, most 
patients with acute symptomatic convulsive status 
epilepticus have either acute metabolic derangement 
(electrolyte imbalance, hypoglycemia, hypocalcemia, or 
hypomagnesemia) or an acute CNS infection. 17, 18 A 
study from Pakistan by Khalid et al.  showed high male 
to female ratio i-e-, 2.4 to 3:1 for these electrolyte 
abnormalities while our study showed that 65.7% were 
females and 34.3% were males (1.9:1) i-e-, high 
female to male ratio (Figure 1). 5
Figure 1: Frequency of normal and abnormal calcium 
and magnesium levels among males & females. 
According to our study, 30% were known epileptics out 
of which 76% were on antiepileptic treatment. Among 
these, there was history of antiepileptic drug withdrawal 
in 50% when they presented in status. In a study by 
Aminoffet al., the etiology, clinical features and 
outcome of status epilepticus in 98 patients over the 
age of 14 years have been reviewed. The most common 
single cause of the status was noncompliance with 
anticonvulsants and this accounted for status in 53% of 
patients which is almost similar to our findings. 19 Non- 
convulsive status epilepticus secondary to hypocalcemia 
has also been reported. Seizures can occur without 
muscular tetany in patients with hypocalcemia. EEG 
changes associated with hypocalcemia include 
evolution from alpha through theta and delta 
dominance. Other EEG findings are generalized spikes, 
sharp-waves burst of delta activity with sharp 
components. 2,20 Because neurologic symptoms of 
electrolyte disorders are functional rather than 
structural, the neurologic manifestations of electrolyte 
disturbances are typically reversible. 11, 12 Electrolyte 
homeostasis in the central nervous system is very 
essential for brain function. 13, 18 Regulation of ionic 
balance is an essential process involving a complex 
array of molecules for moving ions into and out of the 
brain and involving blood–brain barrier function as well 
as mechanisms in the membranes of both neurons and 
glia. Alterations in ion gradients across cellular 
membranes have direct and indirect effects on 
neuronal discharge and may facilitate epileptiform 
activities. 21, 22 Hypocalcemia and hypomagnesemia 
cause mainly CNS neuronal irritability with seizures. 
When the extracellular concentration of calcium ions 
falls below normal, the nervous system becomes 
progressively more excitable, because this causes 
neuronal membrane permeability to sodium ions, 
allowing easy initiation of action potentials. At plasma 
calcium ion concentrations about 50 percent below 
normal, the peripheral nerve fibers become so excitable 
that they begin to discharge spontaneously, initiating 
trains of nerve impulses that passes to the peripheral 
skeletal muscles to elicit tetanic muscle contraction. 
Consequently, hypocalcemia causes tetany and seizures 
because of its action of increasing excitability in the 
brain. As mechanics of calcium at cellular level are 
dependent on serum magnesium levels, hypomagnesemia 
via causing hypocalcemia causes the same (Figure 2). 18, 22
Figure 2: Molecular mechanisms behind seizures 
secondary to hypocalcaemia: Hypocalcaemia facilitates 
movement of sodium ions into the nerve, thus causing 
spontaneous discharge of electrical activity.
Main treatment for hypocalcemic seizures is calcium 
replacement; AEDs are typically not needed. AEDs may 
abolish both overt and latent tetany, whereas hypocalcemic 
seizures remain refractory. However, those in status may 
benefit from AEDs. The inhibition of N-methyl-d-aspartate 
(NMDA) glutamate receptors and the increased production 
of vasodilator prostaglandins in the brain is the 
anticonvulsant action of magnesium. Magnesium serves to 
stabilize neuronal membranes and the lack of it explains 
the tendency to have seizures in the first place. 23, 24 Also, 
mechanism of calcium regulation on neurons is coherent 
with magnesium levels and hypomagnesaemia in itself 
interferes with the action of calcium at cellular level. 12, 16 In 
the setting of seizures or symptomatic or severe (<1.2 
mg/dl, <1 mEq/L) hypomagnesemia, it is advisable to 
inject 1-2 g of MgSO4 (magnesium sulfate) over a 5-min 
period, to be followed by an infusion of 1-2 g of MgSO4 per 
hour for the next few hours. If seizures persist, the bolus 
may be repeated. 17, 24 Serum calcium level is tightly 
regulated by parathyroid hormone (PTH) and 1, 25-dihydox 
-yvitamin D in humans. It is important that one should take 
a look at background factors that have significant effects 
on calcium and its’ regulating hormones. Among these, 
vitamin D insufficiency, magnesium depletion and 
treatment with bisphosphonates, glucocorticoids and 
anticonvulsants are most important. A complete workup of 
epilepsy, therefore, should include workup for calcium, 
magnesium, phosphorus, albumin, vitamin D and PTH 
levels at least in addition to brain imaging and EEG (electro 
encephalogram). 11, 15 Status epilepticus is an under 
diagnosed entity in Pakistan. It is a potentially reversible 
condition but has a high mortality if not recognized and 
managed on time. 25 According to our study, among those 
on antiepileptic drugs, 50% had low calcium levels while 
37.5% had low magnesium levels. Keeping the above 
statistics in mind, it is suggested that patients on long term 
AEDs should at least be worked up once in detail for 
electrolyte abnormalities as timely identification and 
correction can help reduce the morbidity and mortality 
associated with future status epilpeticus. As such, in the 
long run, being a potentially treatable cause, epilepsy 
secondary to electrolyte imbalances can be effectively 
treated without long term unnecessary use of antiepileptics 
and can help reduce both the burden of follow-up epilepsy 
in neurology clinics as well burden of cost on both the 
patients and the health care system.
CONCLUSION
Calcium level was abnormal in 41.4% of patients while 
magnesium was low in 10% of patients. Serum calcium 
level was lower in nearly half while magnesium in nearly 
2/5th of the previously diagnosed epileptics who presented 
in status. Among those on antiepileptic drugs, 50% had low 
calcium levels while 37.5% had low magnesium levels. It is 
suggested that all epileptic patients, especially those on 
long term AEDs, should at least be worked up once in detail 
for electrolyte abnormalities as timely identification and 
correction can help reduce the morbidity and mortality 
associated with future status epilepticus.
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
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observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
INTRODUCTION 
The incidence of status epilepticus ranges from 10.3 to 
61.0 per 100 000 people, with the highest incidence 
reported in populations with low socioeconomic 
standards of living and quality of health care. The 
incidence of status epilepticus is high in the young and 
the old. 1, 2 There are an estimated 3 million cases of 
status epilepticus worldwide each year; of which 70% 
are generalized convulsive status epilepticus (GCSE) 
and about 75% of these cases are overt GCSE. 2, 3 The 
other main category is that of non-convulsive status 
epilepticus (NCSE). GCSE is associated with substantial 
mortality and morbidity. 2, 3 Electrolyte disturbances in the 
ICU are most common. Low magnesium, phosphate, and 
both very low and very high calcium values can cause 
seizures. Critical care physicians must be vigilant to 
suspect and identify electrolyte disturbances in their 
patients, because they are potentially a cause, of poor 
prognosis. 4 The main causes of status epilepticus include 
low blood concentrations of antiepileptic drugs in patients 
with chronic epilepsy, cerebrovascular accidents, anoxia or 
hypoxia, metabolic causes, alcohol or illicit drug 
withdrawal and miscellaneous causes. 5, 6 Despite recent 
improvements in its diagnosis and treatment, status 
epilepticus is still associated with significant mortality. 
Patients presenting with seizures show that main 
laboratory abnormalities present are leukocytosis, 
metabolic acidosis, anemia and hypomagnesaemia. 5 It 
is now common practice to obtain a complete blood 
count and chemistry profiles routinely in patients 
presenting with status epilepticus as electrolytes (e.g. 
sodium, calcium) abnormalities or basic metabolic 
disorders (glucose). 5, 6 The correct diagnosis of seizures 
secondary to these electrolyte abnormalities warrants 
sharp thinking and meticulous search as seizures may 
be the sole presenting symptom of electrolyte 
imbalance. Identification and correction of electrolyte 
imbalances is a potentially manageable ailment that 
can effectively reduce the proportion of morbidity and 
mortality associated with hypocalcemic and hypomagne- 
semic seizures. There is insufficient local data on 
evaluation of electrolyte imbalances in epilepsy in 
Pakistan and therefore, health care takers at primary and 
secondary care levels are unable to acknowledge a 
potentially treatable cause of epilepsy without long term 
use of antiepileptics. The objective of this article is to 
delineate the percentage of people with status 
epilepticus having calcium and magnesium deficiencies 
at admission in order to highlight the importance of early 
recognition and therefore prompt targeted treatment of 
electrolyte related seizures. 
MATERIALS AND METHODS
The study was carried out on inpatient of department of 
Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad from April 2013 to October 2013. 
Seventy patients diagnosed with status epilepticus 
aged more than 12 years were included. The study was 
approved by hospital ethical committee and carried out 
according to international ethical standards of the 
responsible committee on human experimentation and 
with the latest version of Helsinki Declaration of 1975. 
Patients fulfilling the inclusion criteria were enrolled 
after taking informed written consent from the patients 
or relatives. Following information was collected: 
demographic data (age, gender), history of pre-existing 
epilepsy and use of antiepileptic drugs (AED), drug 
withdrawal, noncompliance to medication, clinical 
presentation (to ascertain/ define status epilepticus), 
routine laboratory tests, toxicology screen and brain 
imaging to ascertain the likely cause of status 
epilepticus. Routine laboratory investigations done in all 
patients at admission included complete blood counts, 
ESR, liver function tests, renal function tests, blood 
sugar random, serum electrolytes (sodium, potassium, 
calcium, phosphate and magnesium), urine routine 
examination, urine culture, blood cultures, arterial 
blood gases, serum albumin and AED drug levels. 
Corrected calcium was calculated for those with 
hypoalbuminemia. EEG was done in all patients within 
24 to 48 hours of admission to monitor progress of 
management, to diagnose non-convulsive status 
epilepticus and to rule out other related abnormalities 
(e.g., encephalitis). Lumbar puncture (for CSF routine 
examination) and brain imaging (CT scan or MRI brain) 
was done in selected patients as per indications. All 
patients were managed according to the standard 
protocol for status epilepticus, along with full supportive 
care and cause specific treatment. Causes of status 
epilepticus were identified on the basis of history, 
physical examination, laboratory investigations, and/or 
neuroimaging studies. Factors precipitating status 
epilepticus were classified as: non compliance to 
antiepileptic drug, AED discontinuation within 48 hours 
(drug withdrawal), CNS infection, cerebrovascular 
disease, CNS structural lesions, systemic infections, 
metabolic/ electrolyte disturbances, illicit drugs/alcohol 
abuse, poisoning or idiopathic. The diagnosis of 
idiopathic status epilepticus was made if no apparent 
etiology was identified. The data was analyzed using 
SPSS version 16.0 (USA Inc.). Mean, Median, Mode, 
range and standard deviation were calculated for 
numerical variables i.e. age, serum calcium and 
magnesium. Frequency and percentages were 
presented for categorical variables i.e. gender, serum 
calcium and magnesium (normal, low, high), known 
epileptics, epileptics on AEDs and drug withdrawal.
RESULTS
Mean age was 32.8 ± 5.4 years, median was 27.5 
years and mode was 22 years; with an age range of 77 
(13-90) years. Among the 70 patients, 46 (46 out of 
70; 65.7%) were females and 24 (24 out of 70; 
34.3%) were males (Figure 1). 21 (21 out of 70; 30%) 
were known epileptics out of which 16 (16 out of 21; 
76.1%) were on regular antiepileptic treatment. In 
those patients who were on antiepileptic drugs, there 
was history of antiepileptic drug withdrawal in 8 (8 out 
of 16; 50%) patients when they presented in status. 
Calcium level was low in 29 (29 out of 70; 41.4%) 
patients while it was normal in 41 (41 out of 70; 
58.6%) patients. Range of calcium values was 
1.24-2.50 mmol/ l with mean of 2.13 ± 0.24 mmol/l. 
Previously undiagnosed epileptics had low calcium in 
19 (19 out of 49; 38.7%) patients. Previously 
diagnosed epileptics had low calcium in 10 (10 out of 
21; 47.6%) patients. Those who were on antiepileptic 
drugs, 8 (8 out of 16; 50%) had low calcium levels. 
Overall, 9 (9 out of 24; 37.5%) male patients and 20 
(20 out of 46; 43.4%) females had low calcium values. 
Magnesium level was low only in 7 (7 out of 70; 10%) 
patients and it was normal in 63 (63 out of 70; 90%) 
patients. Range of Magnesium values was 0.25-1.00 
mmol/l with mean value of 0.81 ± 0.15 mmol/l. 
Previously undiagnosed epileptics had low magnesium 
in 4 (4 out of 49; 8.1%) patients. Previously diagnosed 
epileptics had low magnesium in 3 (3 out of 21; 
14.2%) patients. Those who were on antiepileptic 
drugs, 6 (6 out of 16; 37.5%) had low magnesium 
levels. Overall, 2 (2 out of 24; 8.3%) male patients and 
5 (5 out of 46; 10.8%) females had low magnesium 
values. Both calcium & magnesium levels were low in 7 
(7 out of 70; 10%) patients (Figure 1). Comparison of 
gender showed that proportion of status was almost 
double in females (female:male 1.9:1). All those with 
hypomagnesaemia invariably had hypocalcaemia. 
DISCUSSION
Electrolyte abnormalities affect many organs and 
tissues, including the brain. Most of the clinical 
manifestations of electrolyte abnormalities are 
predominantly neurologic and parallel the severity of 
neuronal damage.7, 8 Acute and severe electrolyte 
abnormalities may appear with seizures, or with rapidly 
progressive neurologic symptoms and signs, which 
needs emergency treatment. Seizures are especially 
common in patients with hypocalcemia and 
hypomagnesemia. Seizures occur in 20–25% of 
patients with acute hypocalcemia as a medical 
emergency, and in 30–70% of patients with 
symptomatic hypoparathyroidism. 9, 10 Successful 
management of seizures starts with the establishment 
of an accurate diagnosis of the underlying electrolyte 
abnormalities, because rapid identification and 
correction of the disturbance is important to control 
seizures and prevent permanent brain damage. 11, 12 
Electrolyte (e.g., sodium, calcium) abnormalities or 
basic metabolic disorders (glucose) are reported in 
some patients with status. 13, 14 Generalized tonic- 
clonic, focal motor, and (less frequently) atypical 
absence or akinetic seizures may be the sole presenting 
symptom in hypocalcemia. 10 Generalized tonic–clonic 
seizures can occur in neonates and adults in 
association with severe hypomagnesemia as well. 15, 16 
According to one study, 10% of patients had a 
metabolic disorder as the primary underlying etiology of 
status epilepticus. 13 According to our study, 41.4% of 
patients presenting as status had low calcium level 
which is higher percentage than the percentage 
reported in previous studies. 13 According to our study, 
magnesium level was low in 10% patients who 
presented in status epilepticus. Our results are 
comparable to that of Aguset al. who showed that 
hypomagnesemia occurs in nearly 12 % of hospitalized 
patients. 14 According to Singhiet al., magnesium 
disturbances in critically ill children admitted to 
pediatric intensive care unit show that hypocalcemia 
and hypermagnesaemia occurs in 60% and 4% of 
patients, respectively. The incidence of low RBC-Mg 
(magnesium) in their study was 17.3 episodes per 100 
patient days. Mortality was nine-fold higher in 
hypomagnesemic (30%) compared with normomagna- 
esemic (3.3%) patients. If magnesium and calcium 
both were low, the mortality rate was 33% in contrast to 
nil if both were normal. 17 According to our study, both 
calcium & magnesium levels were low in 10% of 
patients who presented in status. Reportedly, most 
patients with acute symptomatic convulsive status 
epilepticus have either acute metabolic derangement 
(electrolyte imbalance, hypoglycemia, hypocalcemia, or 
hypomagnesemia) or an acute CNS infection. 17, 18 A 
study from Pakistan by Khalid et al.  showed high male 
to female ratio i-e-, 2.4 to 3:1 for these electrolyte 
abnormalities while our study showed that 65.7% were 
females and 34.3% were males (1.9:1) i-e-, high 
female to male ratio (Figure 1). 5
Figure 1: Frequency of normal and abnormal calcium 
and magnesium levels among males & females. 
According to our study, 30% were known epileptics out 
of which 76% were on antiepileptic treatment. Among 
these, there was history of antiepileptic drug withdrawal 
in 50% when they presented in status. In a study by 
Aminoffet al., the etiology, clinical features and 
outcome of status epilepticus in 98 patients over the 
age of 14 years have been reviewed. The most common 
single cause of the status was noncompliance with 
anticonvulsants and this accounted for status in 53% of 
patients which is almost similar to our findings. 19 Non- 
convulsive status epilepticus secondary to hypocalcemia 
has also been reported. Seizures can occur without 
muscular tetany in patients with hypocalcemia. EEG 
changes associated with hypocalcemia include 
evolution from alpha through theta and delta 
dominance. Other EEG findings are generalized spikes, 
sharp-waves burst of delta activity with sharp 
components. 2,20 Because neurologic symptoms of 
electrolyte disorders are functional rather than 
structural, the neurologic manifestations of electrolyte 
disturbances are typically reversible. 11, 12 Electrolyte 
homeostasis in the central nervous system is very 
essential for brain function. 13, 18 Regulation of ionic 
balance is an essential process involving a complex 
array of molecules for moving ions into and out of the 
brain and involving blood–brain barrier function as well 
as mechanisms in the membranes of both neurons and 
glia. Alterations in ion gradients across cellular 
membranes have direct and indirect effects on 
neuronal discharge and may facilitate epileptiform 
activities. 21, 22 Hypocalcemia and hypomagnesemia 
cause mainly CNS neuronal irritability with seizures. 
When the extracellular concentration of calcium ions 
falls below normal, the nervous system becomes 
progressively more excitable, because this causes 
neuronal membrane permeability to sodium ions, 
allowing easy initiation of action potentials. At plasma 
calcium ion concentrations about 50 percent below 
normal, the peripheral nerve fibers become so excitable 
that they begin to discharge spontaneously, initiating 
trains of nerve impulses that passes to the peripheral 
skeletal muscles to elicit tetanic muscle contraction. 
Consequently, hypocalcemia causes tetany and seizures 
because of its action of increasing excitability in the 
brain. As mechanics of calcium at cellular level are 
dependent on serum magnesium levels, hypomagnesemia 
via causing hypocalcemia causes the same (Figure 2). 18, 22
Figure 2: Molecular mechanisms behind seizures 
secondary to hypocalcaemia: Hypocalcaemia facilitates 
movement of sodium ions into the nerve, thus causing 
spontaneous discharge of electrical activity.
Main treatment for hypocalcemic seizures is calcium 
replacement; AEDs are typically not needed. AEDs may 
abolish both overt and latent tetany, whereas hypocalcemic 
seizures remain refractory. However, those in status may 
benefit from AEDs. The inhibition of N-methyl-d-aspartate 
(NMDA) glutamate receptors and the increased production 
of vasodilator prostaglandins in the brain is the 
anticonvulsant action of magnesium. Magnesium serves to 
stabilize neuronal membranes and the lack of it explains 
the tendency to have seizures in the first place. 23, 24 Also, 
mechanism of calcium regulation on neurons is coherent 
with magnesium levels and hypomagnesaemia in itself 
interferes with the action of calcium at cellular level. 12, 16 In 
the setting of seizures or symptomatic or severe (<1.2 
mg/dl, <1 mEq/L) hypomagnesemia, it is advisable to 
inject 1-2 g of MgSO4 (magnesium sulfate) over a 5-min 
period, to be followed by an infusion of 1-2 g of MgSO4 per 
hour for the next few hours. If seizures persist, the bolus 
may be repeated. 17, 24 Serum calcium level is tightly 
regulated by parathyroid hormone (PTH) and 1, 25-dihydox 
-yvitamin D in humans. It is important that one should take 
a look at background factors that have significant effects 
on calcium and its’ regulating hormones. Among these, 
vitamin D insufficiency, magnesium depletion and 
treatment with bisphosphonates, glucocorticoids and 
anticonvulsants are most important. A complete workup of 
epilepsy, therefore, should include workup for calcium, 
magnesium, phosphorus, albumin, vitamin D and PTH 
levels at least in addition to brain imaging and EEG (electro 
encephalogram). 11, 15 Status epilepticus is an under 
diagnosed entity in Pakistan. It is a potentially reversible 
condition but has a high mortality if not recognized and 
managed on time. 25 According to our study, among those 
on antiepileptic drugs, 50% had low calcium levels while 
37.5% had low magnesium levels. Keeping the above 
statistics in mind, it is suggested that patients on long term 
AEDs should at least be worked up once in detail for 
electrolyte abnormalities as timely identification and 
correction can help reduce the morbidity and mortality 
associated with future status epilpeticus. As such, in the 
long run, being a potentially treatable cause, epilepsy 
secondary to electrolyte imbalances can be effectively 
treated without long term unnecessary use of antiepileptics 
and can help reduce both the burden of follow-up epilepsy 
in neurology clinics as well burden of cost on both the 
patients and the health care system.
CONCLUSION
Calcium level was abnormal in 41.4% of patients while 
magnesium was low in 10% of patients. Serum calcium 
level was lower in nearly half while magnesium in nearly 
2/5th of the previously diagnosed epileptics who presented 
in status. Among those on antiepileptic drugs, 50% had low 
calcium levels while 37.5% had low magnesium levels. It is 
suggested that all epileptic patients, especially those on 
long term AEDs, should at least be worked up once in detail 
for electrolyte abnormalities as timely identification and 
correction can help reduce the morbidity and mortality 
associated with future status epilepticus.
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
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observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
INTRODUCTION 
The incidence of status epilepticus ranges from 10.3 to 
61.0 per 100 000 people, with the highest incidence 
reported in populations with low socioeconomic 
standards of living and quality of health care. The 
incidence of status epilepticus is high in the young and 
the old. 1, 2 There are an estimated 3 million cases of 
status epilepticus worldwide each year; of which 70% 
are generalized convulsive status epilepticus (GCSE) 
and about 75% of these cases are overt GCSE. 2, 3 The 
other main category is that of non-convulsive status 
epilepticus (NCSE). GCSE is associated with substantial 
mortality and morbidity. 2, 3 Electrolyte disturbances in the 
ICU are most common. Low magnesium, phosphate, and 
both very low and very high calcium values can cause 
seizures. Critical care physicians must be vigilant to 
suspect and identify electrolyte disturbances in their 
patients, because they are potentially a cause, of poor 
prognosis. 4 The main causes of status epilepticus include 
low blood concentrations of antiepileptic drugs in patients 
with chronic epilepsy, cerebrovascular accidents, anoxia or 
hypoxia, metabolic causes, alcohol or illicit drug 
withdrawal and miscellaneous causes. 5, 6 Despite recent 
improvements in its diagnosis and treatment, status 
epilepticus is still associated with significant mortality. 
Patients presenting with seizures show that main 
laboratory abnormalities present are leukocytosis, 
metabolic acidosis, anemia and hypomagnesaemia. 5 It 
is now common practice to obtain a complete blood 
count and chemistry profiles routinely in patients 
presenting with status epilepticus as electrolytes (e.g. 
sodium, calcium) abnormalities or basic metabolic 
disorders (glucose). 5, 6 The correct diagnosis of seizures 
secondary to these electrolyte abnormalities warrants 
sharp thinking and meticulous search as seizures may 
be the sole presenting symptom of electrolyte 
imbalance. Identification and correction of electrolyte 
imbalances is a potentially manageable ailment that 
can effectively reduce the proportion of morbidity and 
mortality associated with hypocalcemic and hypomagne- 
semic seizures. There is insufficient local data on 
evaluation of electrolyte imbalances in epilepsy in 
Pakistan and therefore, health care takers at primary and 
secondary care levels are unable to acknowledge a 
potentially treatable cause of epilepsy without long term 
use of antiepileptics. The objective of this article is to 
delineate the percentage of people with status 
epilepticus having calcium and magnesium deficiencies 
at admission in order to highlight the importance of early 
recognition and therefore prompt targeted treatment of 
electrolyte related seizures. 
MATERIALS AND METHODS
The study was carried out on inpatient of department of 
Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad from April 2013 to October 2013. 
Seventy patients diagnosed with status epilepticus 
aged more than 12 years were included. The study was 
approved by hospital ethical committee and carried out 
according to international ethical standards of the 
responsible committee on human experimentation and 
with the latest version of Helsinki Declaration of 1975. 
Patients fulfilling the inclusion criteria were enrolled 
after taking informed written consent from the patients 
or relatives. Following information was collected: 
demographic data (age, gender), history of pre-existing 
epilepsy and use of antiepileptic drugs (AED), drug 
withdrawal, noncompliance to medication, clinical 
presentation (to ascertain/ define status epilepticus), 
routine laboratory tests, toxicology screen and brain 
imaging to ascertain the likely cause of status 
epilepticus. Routine laboratory investigations done in all 
patients at admission included complete blood counts, 
ESR, liver function tests, renal function tests, blood 
sugar random, serum electrolytes (sodium, potassium, 
calcium, phosphate and magnesium), urine routine 
examination, urine culture, blood cultures, arterial 
blood gases, serum albumin and AED drug levels. 
Corrected calcium was calculated for those with 
hypoalbuminemia. EEG was done in all patients within 
24 to 48 hours of admission to monitor progress of 
management, to diagnose non-convulsive status 
epilepticus and to rule out other related abnormalities 
(e.g., encephalitis). Lumbar puncture (for CSF routine 
examination) and brain imaging (CT scan or MRI brain) 
was done in selected patients as per indications. All 
patients were managed according to the standard 
protocol for status epilepticus, along with full supportive 
care and cause specific treatment. Causes of status 
epilepticus were identified on the basis of history, 
physical examination, laboratory investigations, and/or 
neuroimaging studies. Factors precipitating status 
epilepticus were classified as: non compliance to 
antiepileptic drug, AED discontinuation within 48 hours 
(drug withdrawal), CNS infection, cerebrovascular 
disease, CNS structural lesions, systemic infections, 
metabolic/ electrolyte disturbances, illicit drugs/alcohol 
abuse, poisoning or idiopathic. The diagnosis of 
idiopathic status epilepticus was made if no apparent 
etiology was identified. The data was analyzed using 
SPSS version 16.0 (USA Inc.). Mean, Median, Mode, 
range and standard deviation were calculated for 
numerical variables i.e. age, serum calcium and 
magnesium. Frequency and percentages were 
presented for categorical variables i.e. gender, serum 
calcium and magnesium (normal, low, high), known 
epileptics, epileptics on AEDs and drug withdrawal.
RESULTS
Mean age was 32.8 ± 5.4 years, median was 27.5 
years and mode was 22 years; with an age range of 77 
(13-90) years. Among the 70 patients, 46 (46 out of 
70; 65.7%) were females and 24 (24 out of 70; 
34.3%) were males (Figure 1). 21 (21 out of 70; 30%) 
were known epileptics out of which 16 (16 out of 21; 
76.1%) were on regular antiepileptic treatment. In 
those patients who were on antiepileptic drugs, there 
was history of antiepileptic drug withdrawal in 8 (8 out 
of 16; 50%) patients when they presented in status. 
Calcium level was low in 29 (29 out of 70; 41.4%) 
patients while it was normal in 41 (41 out of 70; 
58.6%) patients. Range of calcium values was 
1.24-2.50 mmol/ l with mean of 2.13 ± 0.24 mmol/l. 
Previously undiagnosed epileptics had low calcium in 
19 (19 out of 49; 38.7%) patients. Previously 
diagnosed epileptics had low calcium in 10 (10 out of 
21; 47.6%) patients. Those who were on antiepileptic 
drugs, 8 (8 out of 16; 50%) had low calcium levels. 
Overall, 9 (9 out of 24; 37.5%) male patients and 20 
(20 out of 46; 43.4%) females had low calcium values. 
Magnesium level was low only in 7 (7 out of 70; 10%) 
patients and it was normal in 63 (63 out of 70; 90%) 
patients. Range of Magnesium values was 0.25-1.00 
mmol/l with mean value of 0.81 ± 0.15 mmol/l. 
Previously undiagnosed epileptics had low magnesium 
in 4 (4 out of 49; 8.1%) patients. Previously diagnosed 
epileptics had low magnesium in 3 (3 out of 21; 
14.2%) patients. Those who were on antiepileptic 
drugs, 6 (6 out of 16; 37.5%) had low magnesium 
levels. Overall, 2 (2 out of 24; 8.3%) male patients and 
5 (5 out of 46; 10.8%) females had low magnesium 
values. Both calcium & magnesium levels were low in 7 
(7 out of 70; 10%) patients (Figure 1). Comparison of 
gender showed that proportion of status was almost 
double in females (female:male 1.9:1). All those with 
hypomagnesaemia invariably had hypocalcaemia. 
DISCUSSION
Electrolyte abnormalities affect many organs and 
tissues, including the brain. Most of the clinical 
manifestations of electrolyte abnormalities are 
predominantly neurologic and parallel the severity of 
neuronal damage.7, 8 Acute and severe electrolyte 
abnormalities may appear with seizures, or with rapidly 
progressive neurologic symptoms and signs, which 
needs emergency treatment. Seizures are especially 
common in patients with hypocalcemia and 
hypomagnesemia. Seizures occur in 20–25% of 
patients with acute hypocalcemia as a medical 
emergency, and in 30–70% of patients with 
symptomatic hypoparathyroidism. 9, 10 Successful 
management of seizures starts with the establishment 
of an accurate diagnosis of the underlying electrolyte 
abnormalities, because rapid identification and 
correction of the disturbance is important to control 
seizures and prevent permanent brain damage. 11, 12 
Electrolyte (e.g., sodium, calcium) abnormalities or 
basic metabolic disorders (glucose) are reported in 
some patients with status. 13, 14 Generalized tonic- 
clonic, focal motor, and (less frequently) atypical 
absence or akinetic seizures may be the sole presenting 
symptom in hypocalcemia. 10 Generalized tonic–clonic 
seizures can occur in neonates and adults in 
association with severe hypomagnesemia as well. 15, 16 
According to one study, 10% of patients had a 
metabolic disorder as the primary underlying etiology of 
status epilepticus. 13 According to our study, 41.4% of 
patients presenting as status had low calcium level 
which is higher percentage than the percentage 
reported in previous studies. 13 According to our study, 
magnesium level was low in 10% patients who 
presented in status epilepticus. Our results are 
comparable to that of Aguset al. who showed that 
hypomagnesemia occurs in nearly 12 % of hospitalized 
patients. 14 According to Singhiet al., magnesium 
disturbances in critically ill children admitted to 
pediatric intensive care unit show that hypocalcemia 
and hypermagnesaemia occurs in 60% and 4% of 
patients, respectively. The incidence of low RBC-Mg 
(magnesium) in their study was 17.3 episodes per 100 
patient days. Mortality was nine-fold higher in 
hypomagnesemic (30%) compared with normomagna- 
esemic (3.3%) patients. If magnesium and calcium 
both were low, the mortality rate was 33% in contrast to 
nil if both were normal. 17 According to our study, both 
calcium & magnesium levels were low in 10% of 
patients who presented in status. Reportedly, most 
patients with acute symptomatic convulsive status 
epilepticus have either acute metabolic derangement 
(electrolyte imbalance, hypoglycemia, hypocalcemia, or 
hypomagnesemia) or an acute CNS infection. 17, 18 A 
study from Pakistan by Khalid et al.  showed high male 
to female ratio i-e-, 2.4 to 3:1 for these electrolyte 
abnormalities while our study showed that 65.7% were 
females and 34.3% were males (1.9:1) i-e-, high 
female to male ratio (Figure 1). 5
Figure 1: Frequency of normal and abnormal calcium 
and magnesium levels among males & females. 
According to our study, 30% were known epileptics out 
of which 76% were on antiepileptic treatment. Among 
these, there was history of antiepileptic drug withdrawal 
in 50% when they presented in status. In a study by 
Aminoffet al., the etiology, clinical features and 
outcome of status epilepticus in 98 patients over the 
age of 14 years have been reviewed. The most common 
single cause of the status was noncompliance with 
anticonvulsants and this accounted for status in 53% of 
patients which is almost similar to our findings. 19 Non- 
convulsive status epilepticus secondary to hypocalcemia 
has also been reported. Seizures can occur without 
muscular tetany in patients with hypocalcemia. EEG 
changes associated with hypocalcemia include 
evolution from alpha through theta and delta 
dominance. Other EEG findings are generalized spikes, 
sharp-waves burst of delta activity with sharp 
components. 2,20 Because neurologic symptoms of 
electrolyte disorders are functional rather than 
structural, the neurologic manifestations of electrolyte 
disturbances are typically reversible. 11, 12 Electrolyte 
homeostasis in the central nervous system is very 
essential for brain function. 13, 18 Regulation of ionic 
balance is an essential process involving a complex 
array of molecules for moving ions into and out of the 
brain and involving blood–brain barrier function as well 
as mechanisms in the membranes of both neurons and 
glia. Alterations in ion gradients across cellular 
membranes have direct and indirect effects on 
neuronal discharge and may facilitate epileptiform 
activities. 21, 22 Hypocalcemia and hypomagnesemia 
cause mainly CNS neuronal irritability with seizures. 
When the extracellular concentration of calcium ions 
falls below normal, the nervous system becomes 
progressively more excitable, because this causes 
neuronal membrane permeability to sodium ions, 
allowing easy initiation of action potentials. At plasma 
calcium ion concentrations about 50 percent below 
normal, the peripheral nerve fibers become so excitable 
that they begin to discharge spontaneously, initiating 
trains of nerve impulses that passes to the peripheral 
skeletal muscles to elicit tetanic muscle contraction. 
Consequently, hypocalcemia causes tetany and seizures 
because of its action of increasing excitability in the 
brain. As mechanics of calcium at cellular level are 
dependent on serum magnesium levels, hypomagnesemia 
via causing hypocalcemia causes the same (Figure 2). 18, 22
Figure 2: Molecular mechanisms behind seizures 
secondary to hypocalcaemia: Hypocalcaemia facilitates 
movement of sodium ions into the nerve, thus causing 
spontaneous discharge of electrical activity.
Main treatment for hypocalcemic seizures is calcium 
replacement; AEDs are typically not needed. AEDs may 
abolish both overt and latent tetany, whereas hypocalcemic 
seizures remain refractory. However, those in status may 
benefit from AEDs. The inhibition of N-methyl-d-aspartate 
(NMDA) glutamate receptors and the increased production 
of vasodilator prostaglandins in the brain is the 
anticonvulsant action of magnesium. Magnesium serves to 
stabilize neuronal membranes and the lack of it explains 
the tendency to have seizures in the first place. 23, 24 Also, 
mechanism of calcium regulation on neurons is coherent 
with magnesium levels and hypomagnesaemia in itself 
interferes with the action of calcium at cellular level. 12, 16 In 
the setting of seizures or symptomatic or severe (<1.2 
mg/dl, <1 mEq/L) hypomagnesemia, it is advisable to 
inject 1-2 g of MgSO4 (magnesium sulfate) over a 5-min 
period, to be followed by an infusion of 1-2 g of MgSO4 per 
hour for the next few hours. If seizures persist, the bolus 
may be repeated. 17, 24 Serum calcium level is tightly 
regulated by parathyroid hormone (PTH) and 1, 25-dihydox 
-yvitamin D in humans. It is important that one should take 
a look at background factors that have significant effects 
on calcium and its’ regulating hormones. Among these, 
vitamin D insufficiency, magnesium depletion and 
treatment with bisphosphonates, glucocorticoids and 
anticonvulsants are most important. A complete workup of 
epilepsy, therefore, should include workup for calcium, 
magnesium, phosphorus, albumin, vitamin D and PTH 
levels at least in addition to brain imaging and EEG (electro 
encephalogram). 11, 15 Status epilepticus is an under 
diagnosed entity in Pakistan. It is a potentially reversible 
condition but has a high mortality if not recognized and 
managed on time. 25 According to our study, among those 
on antiepileptic drugs, 50% had low calcium levels while 
37.5% had low magnesium levels. Keeping the above 
statistics in mind, it is suggested that patients on long term 
AEDs should at least be worked up once in detail for 
electrolyte abnormalities as timely identification and 
correction can help reduce the morbidity and mortality 
associated with future status epilpeticus. As such, in the 
long run, being a potentially treatable cause, epilepsy 
secondary to electrolyte imbalances can be effectively 
treated without long term unnecessary use of antiepileptics 
and can help reduce both the burden of follow-up epilepsy 
in neurology clinics as well burden of cost on both the 
patients and the health care system.
CONCLUSION
Calcium level was abnormal in 41.4% of patients while 
magnesium was low in 10% of patients. Serum calcium 
level was lower in nearly half while magnesium in nearly 
2/5th of the previously diagnosed epileptics who presented 
in status. Among those on antiepileptic drugs, 50% had low 
calcium levels while 37.5% had low magnesium levels. It is 
suggested that all epileptic patients, especially those on 
long term AEDs, should at least be worked up once in detail 
for electrolyte abnormalities as timely identification and 
correction can help reduce the morbidity and mortality 
associated with future status epilepticus.
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
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observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
INTRODUCTION 
The incidence of status epilepticus ranges from 10.3 to 
61.0 per 100 000 people, with the highest incidence 
reported in populations with low socioeconomic 
standards of living and quality of health care. The 
incidence of status epilepticus is high in the young and 
the old. 1, 2 There are an estimated 3 million cases of 
status epilepticus worldwide each year; of which 70% 
are generalized convulsive status epilepticus (GCSE) 
and about 75% of these cases are overt GCSE. 2, 3 The 
other main category is that of non-convulsive status 
epilepticus (NCSE). GCSE is associated with substantial 
mortality and morbidity. 2, 3 Electrolyte disturbances in the 
ICU are most common. Low magnesium, phosphate, and 
both very low and very high calcium values can cause 
seizures. Critical care physicians must be vigilant to 
suspect and identify electrolyte disturbances in their 
patients, because they are potentially a cause, of poor 
prognosis. 4 The main causes of status epilepticus include 
low blood concentrations of antiepileptic drugs in patients 
with chronic epilepsy, cerebrovascular accidents, anoxia or 
hypoxia, metabolic causes, alcohol or illicit drug 
withdrawal and miscellaneous causes. 5, 6 Despite recent 
improvements in its diagnosis and treatment, status 
epilepticus is still associated with significant mortality. 
Patients presenting with seizures show that main 
laboratory abnormalities present are leukocytosis, 
metabolic acidosis, anemia and hypomagnesaemia. 5 It 
is now common practice to obtain a complete blood 
count and chemistry profiles routinely in patients 
presenting with status epilepticus as electrolytes (e.g. 
sodium, calcium) abnormalities or basic metabolic 
disorders (glucose). 5, 6 The correct diagnosis of seizures 
secondary to these electrolyte abnormalities warrants 
sharp thinking and meticulous search as seizures may 
be the sole presenting symptom of electrolyte 
imbalance. Identification and correction of electrolyte 
imbalances is a potentially manageable ailment that 
can effectively reduce the proportion of morbidity and 
mortality associated with hypocalcemic and hypomagne- 
semic seizures. There is insufficient local data on 
evaluation of electrolyte imbalances in epilepsy in 
Pakistan and therefore, health care takers at primary and 
secondary care levels are unable to acknowledge a 
potentially treatable cause of epilepsy without long term 
use of antiepileptics. The objective of this article is to 
delineate the percentage of people with status 
epilepticus having calcium and magnesium deficiencies 
at admission in order to highlight the importance of early 
recognition and therefore prompt targeted treatment of 
electrolyte related seizures. 
MATERIALS AND METHODS
The study was carried out on inpatient of department of 
Neurology, Pakistan Institute of Medical Sciences 
(PIMS), Islamabad from April 2013 to October 2013. 
Seventy patients diagnosed with status epilepticus 
aged more than 12 years were included. The study was 
approved by hospital ethical committee and carried out 
according to international ethical standards of the 
responsible committee on human experimentation and 
with the latest version of Helsinki Declaration of 1975. 
Patients fulfilling the inclusion criteria were enrolled 
after taking informed written consent from the patients 
or relatives. Following information was collected: 
demographic data (age, gender), history of pre-existing 
epilepsy and use of antiepileptic drugs (AED), drug 
withdrawal, noncompliance to medication, clinical 
presentation (to ascertain/ define status epilepticus), 
routine laboratory tests, toxicology screen and brain 
imaging to ascertain the likely cause of status 
epilepticus. Routine laboratory investigations done in all 
patients at admission included complete blood counts, 
ESR, liver function tests, renal function tests, blood 
sugar random, serum electrolytes (sodium, potassium, 
calcium, phosphate and magnesium), urine routine 
examination, urine culture, blood cultures, arterial 
blood gases, serum albumin and AED drug levels. 
Corrected calcium was calculated for those with 
hypoalbuminemia. EEG was done in all patients within 
24 to 48 hours of admission to monitor progress of 
management, to diagnose non-convulsive status 
epilepticus and to rule out other related abnormalities 
(e.g., encephalitis). Lumbar puncture (for CSF routine 
examination) and brain imaging (CT scan or MRI brain) 
was done in selected patients as per indications. All 
patients were managed according to the standard 
protocol for status epilepticus, along with full supportive 
care and cause specific treatment. Causes of status 
epilepticus were identified on the basis of history, 
physical examination, laboratory investigations, and/or 
neuroimaging studies. Factors precipitating status 
epilepticus were classified as: non compliance to 
antiepileptic drug, AED discontinuation within 48 hours 
(drug withdrawal), CNS infection, cerebrovascular 
disease, CNS structural lesions, systemic infections, 
metabolic/ electrolyte disturbances, illicit drugs/alcohol 
abuse, poisoning or idiopathic. The diagnosis of 
idiopathic status epilepticus was made if no apparent 
etiology was identified. The data was analyzed using 
SPSS version 16.0 (USA Inc.). Mean, Median, Mode, 
range and standard deviation were calculated for 
numerical variables i.e. age, serum calcium and 
magnesium. Frequency and percentages were 
presented for categorical variables i.e. gender, serum 
calcium and magnesium (normal, low, high), known 
epileptics, epileptics on AEDs and drug withdrawal.
RESULTS
Mean age was 32.8 ± 5.4 years, median was 27.5 
years and mode was 22 years; with an age range of 77 
(13-90) years. Among the 70 patients, 46 (46 out of 
70; 65.7%) were females and 24 (24 out of 70; 
34.3%) were males (Figure 1). 21 (21 out of 70; 30%) 
were known epileptics out of which 16 (16 out of 21; 
76.1%) were on regular antiepileptic treatment. In 
those patients who were on antiepileptic drugs, there 
was history of antiepileptic drug withdrawal in 8 (8 out 
of 16; 50%) patients when they presented in status. 
Calcium level was low in 29 (29 out of 70; 41.4%) 
patients while it was normal in 41 (41 out of 70; 
58.6%) patients. Range of calcium values was 
1.24-2.50 mmol/ l with mean of 2.13 ± 0.24 mmol/l. 
Previously undiagnosed epileptics had low calcium in 
19 (19 out of 49; 38.7%) patients. Previously 
diagnosed epileptics had low calcium in 10 (10 out of 
21; 47.6%) patients. Those who were on antiepileptic 
drugs, 8 (8 out of 16; 50%) had low calcium levels. 
Overall, 9 (9 out of 24; 37.5%) male patients and 20 
(20 out of 46; 43.4%) females had low calcium values. 
Magnesium level was low only in 7 (7 out of 70; 10%) 
patients and it was normal in 63 (63 out of 70; 90%) 
patients. Range of Magnesium values was 0.25-1.00 
mmol/l with mean value of 0.81 ± 0.15 mmol/l. 
Previously undiagnosed epileptics had low magnesium 
in 4 (4 out of 49; 8.1%) patients. Previously diagnosed 
epileptics had low magnesium in 3 (3 out of 21; 
14.2%) patients. Those who were on antiepileptic 
drugs, 6 (6 out of 16; 37.5%) had low magnesium 
levels. Overall, 2 (2 out of 24; 8.3%) male patients and 
5 (5 out of 46; 10.8%) females had low magnesium 
values. Both calcium & magnesium levels were low in 7 
(7 out of 70; 10%) patients (Figure 1). Comparison of 
gender showed that proportion of status was almost 
double in females (female:male 1.9:1). All those with 
hypomagnesaemia invariably had hypocalcaemia. 
DISCUSSION
Electrolyte abnormalities affect many organs and 
tissues, including the brain. Most of the clinical 
manifestations of electrolyte abnormalities are 
predominantly neurologic and parallel the severity of 
neuronal damage.7, 8 Acute and severe electrolyte 
abnormalities may appear with seizures, or with rapidly 
progressive neurologic symptoms and signs, which 
needs emergency treatment. Seizures are especially 
common in patients with hypocalcemia and 
hypomagnesemia. Seizures occur in 20–25% of 
patients with acute hypocalcemia as a medical 
emergency, and in 30–70% of patients with 
symptomatic hypoparathyroidism. 9, 10 Successful 
management of seizures starts with the establishment 
of an accurate diagnosis of the underlying electrolyte 
abnormalities, because rapid identification and 
correction of the disturbance is important to control 
seizures and prevent permanent brain damage. 11, 12 
Electrolyte (e.g., sodium, calcium) abnormalities or 
basic metabolic disorders (glucose) are reported in 
some patients with status. 13, 14 Generalized tonic- 
clonic, focal motor, and (less frequently) atypical 
absence or akinetic seizures may be the sole presenting 
symptom in hypocalcemia. 10 Generalized tonic–clonic 
seizures can occur in neonates and adults in 
association with severe hypomagnesemia as well. 15, 16 
According to one study, 10% of patients had a 
metabolic disorder as the primary underlying etiology of 
status epilepticus. 13 According to our study, 41.4% of 
patients presenting as status had low calcium level 
which is higher percentage than the percentage 
reported in previous studies. 13 According to our study, 
magnesium level was low in 10% patients who 
presented in status epilepticus. Our results are 
comparable to that of Aguset al. who showed that 
hypomagnesemia occurs in nearly 12 % of hospitalized 
patients. 14 According to Singhiet al., magnesium 
disturbances in critically ill children admitted to 
pediatric intensive care unit show that hypocalcemia 
and hypermagnesaemia occurs in 60% and 4% of 
patients, respectively. The incidence of low RBC-Mg 
(magnesium) in their study was 17.3 episodes per 100 
patient days. Mortality was nine-fold higher in 
hypomagnesemic (30%) compared with normomagna- 
esemic (3.3%) patients. If magnesium and calcium 
both were low, the mortality rate was 33% in contrast to 
nil if both were normal. 17 According to our study, both 
calcium & magnesium levels were low in 10% of 
patients who presented in status. Reportedly, most 
patients with acute symptomatic convulsive status 
epilepticus have either acute metabolic derangement 
(electrolyte imbalance, hypoglycemia, hypocalcemia, or 
hypomagnesemia) or an acute CNS infection. 17, 18 A 
study from Pakistan by Khalid et al.  showed high male 
to female ratio i-e-, 2.4 to 3:1 for these electrolyte 
abnormalities while our study showed that 65.7% were 
females and 34.3% were males (1.9:1) i-e-, high 
female to male ratio (Figure 1). 5
Figure 1: Frequency of normal and abnormal calcium 
and magnesium levels among males & females. 
According to our study, 30% were known epileptics out 
of which 76% were on antiepileptic treatment. Among 
these, there was history of antiepileptic drug withdrawal 
in 50% when they presented in status. In a study by 
Aminoffet al., the etiology, clinical features and 
outcome of status epilepticus in 98 patients over the 
age of 14 years have been reviewed. The most common 
single cause of the status was noncompliance with 
anticonvulsants and this accounted for status in 53% of 
patients which is almost similar to our findings. 19 Non- 
convulsive status epilepticus secondary to hypocalcemia 
has also been reported. Seizures can occur without 
muscular tetany in patients with hypocalcemia. EEG 
changes associated with hypocalcemia include 
evolution from alpha through theta and delta 
dominance. Other EEG findings are generalized spikes, 
sharp-waves burst of delta activity with sharp 
components. 2,20 Because neurologic symptoms of 
electrolyte disorders are functional rather than 
structural, the neurologic manifestations of electrolyte 
disturbances are typically reversible. 11, 12 Electrolyte 
homeostasis in the central nervous system is very 
essential for brain function. 13, 18 Regulation of ionic 
balance is an essential process involving a complex 
array of molecules for moving ions into and out of the 
brain and involving blood–brain barrier function as well 
as mechanisms in the membranes of both neurons and 
glia. Alterations in ion gradients across cellular 
membranes have direct and indirect effects on 
neuronal discharge and may facilitate epileptiform 
activities. 21, 22 Hypocalcemia and hypomagnesemia 
cause mainly CNS neuronal irritability with seizures. 
When the extracellular concentration of calcium ions 
falls below normal, the nervous system becomes 
progressively more excitable, because this causes 
neuronal membrane permeability to sodium ions, 
allowing easy initiation of action potentials. At plasma 
calcium ion concentrations about 50 percent below 
normal, the peripheral nerve fibers become so excitable 
that they begin to discharge spontaneously, initiating 
trains of nerve impulses that passes to the peripheral 
skeletal muscles to elicit tetanic muscle contraction. 
Consequently, hypocalcemia causes tetany and seizures 
because of its action of increasing excitability in the 
brain. As mechanics of calcium at cellular level are 
dependent on serum magnesium levels, hypomagnesemia 
via causing hypocalcemia causes the same (Figure 2). 18, 22
Figure 2: Molecular mechanisms behind seizures 
secondary to hypocalcaemia: Hypocalcaemia facilitates 
movement of sodium ions into the nerve, thus causing 
spontaneous discharge of electrical activity.
Main treatment for hypocalcemic seizures is calcium 
replacement; AEDs are typically not needed. AEDs may 
abolish both overt and latent tetany, whereas hypocalcemic 
seizures remain refractory. However, those in status may 
benefit from AEDs. The inhibition of N-methyl-d-aspartate 
(NMDA) glutamate receptors and the increased production 
of vasodilator prostaglandins in the brain is the 
anticonvulsant action of magnesium. Magnesium serves to 
stabilize neuronal membranes and the lack of it explains 
the tendency to have seizures in the first place. 23, 24 Also, 
mechanism of calcium regulation on neurons is coherent 
with magnesium levels and hypomagnesaemia in itself 
interferes with the action of calcium at cellular level. 12, 16 In 
the setting of seizures or symptomatic or severe (<1.2 
mg/dl, <1 mEq/L) hypomagnesemia, it is advisable to 
inject 1-2 g of MgSO4 (magnesium sulfate) over a 5-min 
period, to be followed by an infusion of 1-2 g of MgSO4 per 
hour for the next few hours. If seizures persist, the bolus 
may be repeated. 17, 24 Serum calcium level is tightly 
regulated by parathyroid hormone (PTH) and 1, 25-dihydox 
-yvitamin D in humans. It is important that one should take 
a look at background factors that have significant effects 
on calcium and its’ regulating hormones. Among these, 
vitamin D insufficiency, magnesium depletion and 
treatment with bisphosphonates, glucocorticoids and 
anticonvulsants are most important. A complete workup of 
epilepsy, therefore, should include workup for calcium, 
magnesium, phosphorus, albumin, vitamin D and PTH 
levels at least in addition to brain imaging and EEG (electro 
encephalogram). 11, 15 Status epilepticus is an under 
diagnosed entity in Pakistan. It is a potentially reversible 
condition but has a high mortality if not recognized and 
managed on time. 25 According to our study, among those 
on antiepileptic drugs, 50% had low calcium levels while 
37.5% had low magnesium levels. Keeping the above 
statistics in mind, it is suggested that patients on long term 
AEDs should at least be worked up once in detail for 
electrolyte abnormalities as timely identification and 
correction can help reduce the morbidity and mortality 
associated with future status epilpeticus. As such, in the 
long run, being a potentially treatable cause, epilepsy 
secondary to electrolyte imbalances can be effectively 
treated without long term unnecessary use of antiepileptics 
and can help reduce both the burden of follow-up epilepsy 
in neurology clinics as well burden of cost on both the 
patients and the health care system.
CONCLUSION
Calcium level was abnormal in 41.4% of patients while 
magnesium was low in 10% of patients. Serum calcium 
level was lower in nearly half while magnesium in nearly 
2/5th of the previously diagnosed epileptics who presented 
in status. Among those on antiepileptic drugs, 50% had low 
calcium levels while 37.5% had low magnesium levels. It is 
suggested that all epileptic patients, especially those on 
long term AEDs, should at least be worked up once in detail 
for electrolyte abnormalities as timely identification and 
correction can help reduce the morbidity and mortality 
associated with future status epilepticus.
REFERENCES
1.   Galindo Zavala R, Ramos Fernandez JM, Cordon 
     Martinez AM, Urda Cardona AL. Convulsive status 
     due to hypocalcemia in a toddler secondary to 
     maternal vitamin D deficiency. AnPediatr (Barc). 
     2013; 78(1):65-7. 
2.   Siddiqui M, Jamil N, Malik A, Bano A, Khan FS, 
     Siddiqui K. Frequency of non convulsive status 
     epilepticus in patients with impaired level of 
     consciousness. J Pak Med Assoc. 2009;59(5):296-8.
3.   Treiman DM. Importance of early recognition and 
      treatment of generalised convulsive status epilepticus. 
     Lancet Neurol. 2008; 7:667-8.
4.   Robinson J,   Suarez JI. Electrolyte Disturbance 
     and Critical Care Seizures. Current Clinical Neurology. 
     2005, 217-36 
5.   Ahmed K, Jafr SK, Bhatti F, Rafique A, Haque A. 
     Clinical profile and outcome of children admitted 
     with status epileptics in PICU of a developing 
     country. Pak J Neurological Sci. 2013; 8(2):1-6. 
6.   Modi S, Tripathi M, Saha S, Goswami R. Seizures 
     in patients with idiopathic hypoparathyroidism: 
     effect of antiepileptic drug withdrawal on recurrence 
     of seizures and serum calcium control. Eur J 
     Endocrinol. 2014; 170(5):777-83.
7.   Hamed SA, Moussa EM, Youssef AH, AbdEl 
     Hameed MA, NasrEldin E. Bone status in patients 
     with epilepsy: relationship to markers of bone 
     remodeling. Front Neurol. 2014; 5:142.
8.   Moccia M, Erro R, Nicolella E, Striano P, Striano S. 
     Extreme startle and photomyoclonic response in 
     severe hypocalcaemia. Epileptic Disord. 2014;16 
     (1):84-7.
9.   Ndiaye M, Dehanin T, Sow AD, Sene MS, Basse 
     AM, Fall AL, et al. Familial congenital hypomagnes- 
     emia revealed by neonatal convulsions. Arch 
     Pediatr. 2013; 20(11):1212-8.
10. Riviello JJ, Ashwal S, Hirtz D ,Glauser T, 
     Ballaban-Gil K, Kelley K et al. Practice Parameter : 
     Diagnostic assessment of the child with status 
     epilepticus (an evidence based review). Neurology. 
     2006; 67:1542-1550.
11. Rana AQ, Rana AN, Adlul A, Khan A. Chorea and 
     seizures in iatrogenic hypocalcaemia caused by 
     accidental parathyroidectomy. Br J Hosp Med. 
     2012; 73(8):470-1.
12. Belluzzo M, Monti F, Pizzolato G. A case of 
     hypocalcemia-related epilepsiapartialis continua. 
     Seizure. 2011; 20(9):720-2.
13. Riggs JE. Neurological manifestations of electrolyte 
     disturbances. Neurology Clinics. 2002; 20:227–39.
14. Agus, ZS. Hypomagnesaemia. J Am SocNephrol. 
     1999; 10:1616.
15. Maeda K, Sekine O. Reading epilepsy as the initial 
     symptom of idiopathic hypoparathyroidism. Intern 
     Med. 2011; 50(11):1235-7.
16. Visudhiphan P, Visudtibhan A, Chiemchanya S, 
     Khongkhatithum C. Neonatal seizures and familial 
     hypomagnesemia with secondary hypocalcemia. 
     Pediatr Neurol. 2005; 33(3):202-5.
17. Singhi SC, SinghJ and Prasad R.Hypo- and 
     Hypermagnesemia in an Indian Pediatric Intensive 
     Care Unit.  Journal of Tropical Pediatrics. 2003; 
     49(2):99-103.
18. Chin RF, Neville BG, Peckham C, Bedford H, Wade 
     A, Scott RC; NLSTEPSS Collaborative Group. 
     Incidence, cause, and short-term outcome of 
     convulsive status epilepticus in childhood: 
     prospective population-based study. Lancet. 
     2006; 368:222-29.
19. Aminoff MJ, Simon RP. Status epilepticus. Causes, 
     clinical features and consequences in 98 patients. 
     Am J. Med. 1980; 69(5):657-66.
20. Khatri IA, Iannaccone ST, Ilyas MS, Abdullah M, 
     Saleem S. Epidemiology of epilepsy in Pakistan: 
     review of literature. J Pak Med Assoc. 2003; 53:594-7.
21. Castilla-Guerra L, del Carmen Fernandez-Moreno 
     M, Lopez-Chozas JM. Fernandez-Bolanos R. 
     Electrolytes disturbances and seizures. Epilepsia. 
     2006; 47(12):1990-8.
22. Kumar M, Kumari R, Narain NP. Clinical Profile of 
     Status epilepticus (SE) in Children in a Tertiary 
     Care Hospital in Bihar. J ClinDiagn Res. 2014; 
     8(7):14-7.
23. Kidwell KS, Kopp WE, Albano EA, Brown AE. 
     "Ghosts in my body": Seizure-like presentation of 
      hypocalcemictetany secondary to hypomagnesemia 
     in a patient receiving cetuximab therapy for 
     metastatic medulloblastoma. J PediatrHematolOncol. 
     2014; 36(4):305-7.
24. Weisleder P, Tobin JA, Kerrigan JF 3rd, 
     Bodensteiner JB. Hypomagnesemic seizures: case 
     report and presumed pathophysiology. J Child 
     Neurol. 2002; 17(1):59-61.
25. Siddiqi F. Epilepsy: the Pakistan perspective some 
     suggestions. Pak J Neurological Sci. 2013; 8(2):1-2.
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
2 6 V O L .  1 0  ( 3 )  J U L   -   S E P T   2 0 1 5P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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